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Abstract
Although oral PrEP is highly effective at preventing HIV acquisition, optimizing continuation among beneficiaries is chal-
lenging in many settings. We estimated the costs of delivering oral PrEP to populations at risk of HIV in seven clinics in 
Zimbabwe. Full annual economic costs of oral PrEP initiations and continuation visits were estimated from the providers’ 
perspective for a six-clinic NGO network and one government SGBV clinic in Zimbabwe (January–December 2018). Disag-
gregating costs of full initiation and incremental follow-up visits enabled modeling of the impact of duration of continuation 
on the cost per person-year ($pPY) on PrEP. 4677 people initiated oral PrEP, averaging 2.7 follow-up visits per person. 
Average cost per person initiated was $238 ($183–$302 across the NGO clinics; $86 in the government facility). The full 
cost per initiation visit, including central and direct costs, was $178, and the incremental cost per follow-up visit, capturing 
only additional resources used directly in the follow up visits, was $22. The average duration of continuation was 3.0 months, 
generating an average $pPY of $943, ranging from $839 among adolescent girls and young women to $1219 in men. Oral 
PrEP delivery costs varied substantially by scale of initiations and by duration of continuation and type of clinic. Extending 
the average oral PrEP continuation from 2.7 to 5 visits (about 6 months) would greatly improve service efficiency, cutting 
the $pPY by more than half.
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Introduction
Sub-Saharan Africa (SSA) is home to nearly 61% of peo-
ple living with HIV (PLHIV) globally [1]. Zimbabwe is 
among the countries worst affected, with an adult HIV 
prevalence of 14.7% and 1.2 million PLHIV [2]. In 2019 
alone, 20,000 AIDS-related deaths and 40,000 new HIV 
infections were recorded in Zimbabwe [1]. Existing HIV 
prevention approaches, though often widely available at 
no cost in resource-limited settings, have been either char-
acterized by low uptake in the case of voluntary medi-
cal male circumcision (VMMC) or inconsistently used 
in the case of male and female condoms [3–6]. Evidence 
from clinical trials showing effectiveness at preventing 
HIV acquisition of up to 96% when oral pre-exposure 
prophylaxis (PrEP) is combined with appropriate clini-
cal monitoring led to the WHO guidelines recommending 
tenofovir-based daily oral PrEP for those at substantial 
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risk of HIV acquisition [7, 8]. PrEP has also proven highly 
effective as a “bridge” to sustained antiretroviral therapy 
(ART) use for serodiscordant couples, with the HIV-seron-
egative partner taking the drug for a limited time when 
the HIV-seropositive partner is on ART but not yet virally 
suppressed or is not yet on ART [9–12].
In line with WHO guidance [13, 14], some countries 
with high HIV burdens introduced oral PrEP as part of 
their HIV prevention services. In 2016, Zimbabwe’s Min-
istry of Health and Child Care (MoHCC) launched the 
Consolidated Guidelines for Antiretroviral Therapy for the 
Prevention and Treatment of HIV in Zimbabwe [15]. These 
guidelines recommend oral PrEP to all individuals who 
are not living with HIV and perceive themselves to be at 
relatively high risk of HIV infection. Potentially eligible 
populations include adolescent girls and young women 
(AGYW), pregnant women in relationships with men of 
unknown status, HIV-seronegative partners in serodiscord-
ant relationships, female and male sex workers (SWs), 
high-risk men who have sex with men (MSM), prisoners, 
long-distance truck drivers and transgender women.
For Zimbabwe, oral PrEP was initially introduced as part 
of the PEPFAR-funded Determined, Resilient, Empowered, 
AIDS-free, Mentored and Safe (DREAMS) initiative that 
aims to reduce HIV incidence among AGYW. PrEP was 
subsequently expanded to key populations (KPs), particu-
larly MSM, transgender people, female SWs, serodiscordant 
couples, young women who sell sex and married people 
at substantial risk of HIV [16]. As oral PrEP delivery is 
scaled up across the country, an important consideration 
for MoHCC policy makers, funders and program imple-
menters is how to optimize coverage and adherence among 
high-risk populations to maximize population‐level impact 
[17]. However, a dearth of program and unit cost data are 
available to facilitate optimization decisions both within 
and outside Zimbabwe, because few studies have attempted 
to estimate the initiation and continuation costs of PrEP 
delivery [17–19]. To our knowledge, no published study has 
estimated the costs of PrEP delivery in Zimbabwe to date.
To help bridge this evidence gap, we conducted a cost-
ing study to estimate the annual total program and unit 
costs of initiating and supporting continuation of clients on 
oral PrEP. This costing study was conducted in six social 
franchise clinics run by a non-governmental organization 
(NGO), Population Services International (PSI) Zimbabwe, 
offering integrated HIV and sexual and reproductive health 
(SRH) services across five provinces and in one govern-
ment sexual and gender-based violence (SGBV) clinic in 
Zimbabwe. The primary costing objectives were to provide 
input into cost-effectiveness modeling and data for assessing 
resource needs associated with scaling up PrEP delivery. We 
also modeled the variation in cost per person-year on PrEP 
($pPY) based on duration of continuation.
Methods
Study Setting
In 2017, PSI began providing oral PrEP as part of the 
package of SRH services offered to the general popula-
tion, including key populations, in its stand-alone New 
Start Centre (NSC) clinics, which have been in operation 
since 1999 [20]. These clinics include the DREAMS-
supported PSI sites in Bulawayo, Gweru, Mutare and 
Chipinge and the non-DREAMS sites in Harare and 
Masvingo [16]. In addition, a government 24–h SGBV 
clinic in Harare has offered oral PrEP integrated in exist-
ing services for KPs since June 2017 [21]. The MoHCC-
approved regimen is a daily fixed-dose combination of 
300 mg tenofovir disoproxil fumarate (TDF) and 200 mg 
emtricitabine (FTC) or lamivudine (3TC).
The costing study was undertaken in the six PSI clinics 
and the government SGBV clinic, where PrEP services are 
offered for free alongside other SRH and HIV prevention 
and treatment services implemented by private non-profit 
providers supported by PEPFAR. The 7 clinic sites were 
selected on the basis that they were the only ones in Zim-
babwe that met the inclusion criterion of having delivered 
PrEP for at least 12 months to allow a full year’s cost-
ing. Sites were either stand alone or co-located with other 
clinics and were located in regions across the country in 
both small towns and large urban areas. Table 1 shows 
the characteristics of the sites which include the PSI-run 
sites (columns 1–4, 6), a clinic that PSI subcontracted to 
an implementing partner (column 5) and the government 
SGBV site (column 7). Further details of the services pro-
vided at the sites can be found in supplemental Table A1.
Community Mobilization by Trained Enhanced Peer 
Mobilizers
For the non-governmental providers, community PrEP 
mobilization is conducted by a cadre of trained, part-time 
enhanced peer mobilizers (EPMs) representing lesbian, 
gay, bisexual, transgender and intersex (LGBTI) people 
and female SWs [22]. The EPMs, who work under a KP 
officer whose role is to provide support when required, 
are responsible for recruiting and linking clients to HIV 
testing services (HTS) during community outreach events. 
These activities are conducted outside normal working 
hours, typically at night, in one-on-one or small-group 
interpersonal communication sessions covering the ben-
efits of testing, PrEP and ART use. Identified HIV-positive 
people are linked to ART services for care and treatment, 
while those who are HIV negative are referred to PrEP 
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services. EPMs are paid a monthly $40 stipend. They also 
earn a pay-for-performance incentive of $10 for each per-
son they test and successfully link to ART or PrEP.
Typical Client Flow at PrEP Services
The annual follow-up schedule involves a total of eight visits 
for the government SGBV clinic and seven for the PSI facili-
ties (Supplemental Table A2) as clients receive test results 
during the initiation visit. At the PSI clinics, clients present 
at reception for registration, proceed to HTS for confirma-
tory testing, and then see a PrEP provider for assessment 
of HIV risk and PrEP readiness prior to initiation. A peer 
counselor provides continuation advice and support while 
the client awaits test results and collection of PrEP drugs 
from the onsite clinic pharmacy and on the same day. A 
2-week follow-up visit is booked for collection of blood test 
results. In the government clinic, an SGBV-trained nurse 
provides all the information and confirms HIV status, com-
pletes a PrEP risk assessment form, takes blood for diagnos-
tics (liver function tests, full blood count, syphilis, creatinine 
and hepatitis B) and initiates a client on the same day with 
a 1-month drug supply. Clients are booked to return for a 
one-week follow-up visit to receive their blood test results.
Cost Data Collection
We estimated the full economic cost of initiating and con-
tinuously engaging clients on oral PrEP from the providers’ 
perspective. This economic cost analysis includes actual 
financial costs incurred by both the PSI and government 
PrEP sites plus any donated goods and services and vol-
unteer time, representing the full value of the resources 
used for PrEP service provision [23, 24]. The latter were 
accounted for during activity-based costing and site observa-
tions [25]. From November 2018 through January 2019, we 
collated financial reports and the associated PrEP monitor-
ing and evaluation data to estimate the annual resource use 
for the retrospective 12-month period.
Cost Analysis
The costing methods combined top-down expenditures 
analysis with ingredients-based costing consistent with 
guidelines [26–28]. The full economic costs for PrEP ser-
vices were classified into two major cost categories: capital 
(including start-up training) and recurrent costs. The start-
up costs of the initial training were treated as capital costs, 
because programs were assumed to benefit over a longer 
period, typically three to four years. Costs were further cat-
egorized by input type. Capital costs (including building 
space, equipment and vehicles) were amortized at a 3% dis-
count rate [23, 24]. Time allocation sheets were analyzed 
using a time and motion exercise involving both self-reports 
and observation of staff providing PrEP and other services 
[29, 30].
Recurrent costs were comprised of personnel (both direct 
and support), management and administration, PrEP drugs, 
laboratory, pharmacy and promotional supplies, HIV tests, 
demand creation, and vehicle and building operation and 
maintenance costs [27]. The PrEP-related laboratory tests 
included chemistry analysis (creatinine test) and serology 
Table 1  Site characteristics for 7 Zimbabwe sites offering PrEP (2018)
Site Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 Site 7
Management NGO site NGO site NGO site NGO site NGO partner 
run site
NGO site Government 
SGBV site




Large city Medium size 
city
Small town Large city
Site location City stand-alone City health 
clinic
City stand-alone City stand-alone City stand-alone City stand-alone City health clinic





124,124 5070 22,356 53,214 28,217 3614 63,928
PrEP program 
start date




















29 27 29 32 32 29 18
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tests (syphilis, hepatitis B and pregnancy, as well as drug 
resistance tests for those who seroconvert while on PrEP).
In addition to the full fixed costs, as described above, 
we also estimated the incremental variable costs associated 
with each continuation visit and by specific population group 
(men—all ages; women—25 years and older; AGYW—15 
to 24 years). Total program variable costs were estimated 
for all inputs related to continuation visits, such as staffing, 
PrEP drugs, HIV tests, follow-up calls and home visits. This 
approach allows us to estimate annual cost per client on oral 
PrEP as a function:
We estimate the number of people needing to be initiated to 
achieve a full year of receiving oral PrEP as:
And the cost per person year ($pPY) receiving oral PrEP is 
estimated as a function of  QinitiatesNeeded:
This function estimates how the $pPY on PrEP decreases as 
the duration of PrEP use increases. Average costs per client 
on PrEP decrease because the high fixed initiation costs are 
spread over more months of benefits.
Sensitivity Analysis
To assess the impact of varying assumptions on the average 
cost per person initiated and per person continuing PrEP at 
3 and 6 months, we conducted one-way sensitivity analy-
ses [28]. Amortization time frames (economic life-years) 
for the initial training were varied between 1 and 6 years 
(base case is 4 years) and for furniture and equipment by 
5 to 7 years (base case is 3 years) to assess the impact of 
project duration. We also conducted analyses to assess the 
impact of various scenarios (personnel salary, discounting, 
annual throughput, price of PrEP drug and PrEP program, 
with or without incentive for initiation) in anticipation of 
future program scale-up. Best- and worst-case scenarios, 
with all parameters yielding lowest/highest average cost per 
person initiated and continuously engaged on PrEP at 3 and 
6 months, were estimated.
Ethics
The MoHCC of Zimbabwe granted permission to conduct 
the study. Ethical approvals were obtained from the Medi-
cal Research Council of Zimbabwe (June 20, 2018) and the 
(1)$ per client = f
(
$fixed initiation + number of continuation visits ∗ $ continuation visit
)
(2)
QInitiatesNeeded = 12 months∕average continuation duration in months
(3)$pPY receiving oral PrEP = $Initiation ∗ QInitiationsNeeded + $Continuation visit ∗ QContinuationVisits pp ∗ QInitiationsNeeded
London School of Hygiene and Tropical Medicine Ethics 
Committee (April 18, 2018).
Results
Program Outcomes
Table 1 shows site characteristics including clinic location 
and size in visits per year. From January through December 
2018, 4617 clients initiated oral PrEP at PSI clinics includ-
ing the partner run site, ranging from 351 clients in Site 3 to 
1599 clients in Site 1 (Table 2). At 3 and 6 months, respec-
tively, 2099 (45%, range 10% to 79% across clinic sites) and 
1142 (25%, range 7% to 47%) clients continued on PrEP in 
the PSI facilities. The government SGBV clinic initiated 60 
clients on PrEP, with 17 (28%) and five (8%) continuing at 
three and six months, respectively. There were an average 
of 2.7 visits per client.
Total Costs and Cost Composition
The total annual program costs were $1,113,430 across 
the seven sites, with recurrent costs contributing 93% 
($1,036,199) of the cost (Table 2); personnel was one-third 
of the cost. For the PSI sites, demand creation including 
mobilizer costs contributed 27% to the cost (Supplemen-
tal Fig. A1), and PrEP drugs 9%. For the government 
SGBV clinic, the largest cost (25%) was the PrEP drug (Sup-
plemental Fig. A2).
Average Costs
Table 2 shows average costs per person on PrEP for all seven 
sites and the breakdown of inputs. The average cost per per-
son initiated on PrEP was $238, ranging from $183 at the 
largest PSI facility in Harare (Site 1) to $302 at the small 
clinic in a medium size town (Site 5) and $86 at the govern-
ment SGBV clinic. Figure 1 shows average cost across popu-
lations, plotted against numbers initiated and continuing at 
months 3 and 6 across the six PSI sites. When assessed by 
population, the average costs per person initiated on PrEP 
across facilities appear similar, being lowest for all males 
(all ages) at $215, followed by $240 for AGYWs (ages 15 to 
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24), and highest for women (25 and older) at $243. Due to 
variable periods of engagement, average cost per client con-
tinuing on PrEP ranged from $347 to $2282 at three months 
and from $644 to $3424 at six months in the PSI sites. For 
the government SGBV clinic, the average cost per client 
continuing on PrEP at three and six months was $303 and 
$1029, respectively.
Incremental Fixed and Variable Costs
We modeled the incremental costs of PrEP continuation 
visits, i.e., only those costs directly used, excluding any 
shared costs. Taking the full annual costs of PrEP provi-
sion minus the total incremental continuation costs generates 
the estimated full cost of initiation. To get the full cost per 
PrEP initiation and incremental cost per PrEP continuation 
visit, we divided the total costs by their respective outputs, 
i.e., initiations and continuation visits, as shown in Table 3. 
Across the clinics, the fully loaded fixed cost of a PrEP ini-
tiation visit was $178, and the incremental cost per follow-up 
PrEP visit was $22.
Using these fixed and variable costs per person, we can 
model the $pPY for different durations of PrEP continu-
ation. We first estimated the number of people who need 
to be initiated to achieve 12 months of receiving oral PrEP 
following Eq. 2. To estimate the $pPY of receiving oral 
PrEP, commonly used in impact models, we applied Eq. 3. 
For example, a person-year on PrEP could be one person 
Table 2  Full economic and unit costs per PrEP client initiated and continued to 3 and 6 months at 7 Zimbabwe sites offering PrEP (2018)




 Buildings and storage $3930 $954 $3540 $1898 $6470 $1202 $673 $18,666 2%
 Site level equipment $4851 $3961 $1101 $2200 $1751 $535 $164 $14,565 1%
 Vehicles $10,152 $6016 $3659 $5025 $7972 $5859 – $38,683 3%
 Start-up training (EPM's) $64 $563 $229 $63 $422 – $94 $1435 0%
 Start-up training (Provider's) $979 $377 $603 $904 $603 $301 $115 $3888 0%
 Total capital $19,976 $11,871 $9132 $10,090 $17,218 $7897 $1047 $77,253 7%
Recurrent costs 0%
 Management & administration $6200 $8208 $5001 $5386 $8427 $948 – $34,169 3%
 Personnel—direct $59,196 $9233 $10,416 $34,145 $58,369 $44,823 $287 $216,469 19%
 Personnel—support $32,746 $24,426 $20,588 $34,372 $30,157 $5683 $97 $148,068 13%
 PrEP drug $25,902 $5431 $4297 $24,998 $28,068 $19,567 $1302 $109,567 10%
 Other pharmacy supplies $823 – $89 – $5283 – – $6195 1%
 Lab supplies $8228 $2571 $1805 $3312 $4150 $3682 $334 $24,082 2%
 Promotional supplies $557 $194 $197 $443 $368 – $569 $2329 0%
 HIV tests $21,488 $5364 $3924 $17,267 $17,749 $13,534 $680 $80,006 7%
 Demand creation—sub-grants $85,287 $35,304 $15,100 $29,839 $58,499 $88,370 – $312,399 28%
 Demand creation—EPM incentives $21,377 $6496 $5606 $10,562 $13,551 – $831 $58,422 5%
 Vehicle operation, & maintenance $10,828 $7076 $6948 $6728 $2039 $7548 – $41,167 4%
 Building operation, & maintenance $22 $231 $303 $39 $103 $2627 – $3326 0%
 Total recurrent $272,655 $104,534 $74,274 $167,091 $226,763 $186,782 $4100 $1,036,199 93%
 TOTAL $292,631 $116,405 $83,406 $177,181 $243,981 $194,679 $5147 $1,113,430 100%
# PrEP clients initiated: AGYW 328 167 93 226 291 530 6 1641 1641
# PrEP clients initiated: adult women 601 35 107 298 203 112 37 1393 1393
# PrEP clients initiated: all men 670 298 151 120 313 74 17 1643 1643
# PrEP clients initiated: all 1599 500 351 644 807 716 60 4677
 Cost per PrEP client initiated $183 $233 $238 $275 $302 $272 $86 $238
# PrEP clients continued to 3 months 412 51 58 510 574 494 17 2116
 Cost per PrEP client continued to 3 months $710 $2282 $1438 $347 $425 $394 $303 $526
# PrEP clients continued to 6 months 236 34 32 213 379 248 5 1147
 Cost per PrEP client continued to 6 months $1240 $3424 $2606 $832 $644 $785 $1029 $971
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who continues for a year or 12 people who continue for a 
month. An estimate of the cost of the former would add the 
cost of one initiation visit and seven follow-up visits, while 
the latter would incur the cost of 12 initiation visits and 12 
follow-up visits (see the annual visit schedule in Supple-


























































AGYW Adult women All men
Average connuaon in weeks: 
15 15.4 9.3
Fig. 1  PrEP uptake (M0) and continuation at 3 and 6 months and average costs by population (PSI Zimbabwe only) (2018)
Table 3  Average cost per continuation visit and per person initiated excluding continuation visit costs at 7 Zimbabwe sites offering PrEP (2018)
a Incremental cost per continuation visit = Total incremental continuation cost/#continuation visits; Full cost of initiation visits = Total PrEP 
delivery costs—Total incremental continuation costs; Full cost per initiation visit = Full cost of initiation visits/ #initiation visits; Average cost 
per person year: Eq. 2, e.g. site 1: $143*(12/1.8)
Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 Site 7 All Sites
Total PrEP delivery costs $292,631 $116,405 $83,406 $177,181 $243,981 $194,679 $5147 $1,113,430
Incremental cost of continuation visits
ART/PrEP clinician $9858 $1878 $1446 $11,483 $12,691 $9199 $374 $46,930
Site doctor $58 $35 $26 $181 $222 $239 $0 $760
Pharmacy technician $12,675 $2415 $1859 $14,764 $16,317 $11,827 $374 $60,231
PrEP peers & champions: allowances & home visits $5400 $3240 $2700 $2160 $7425 $20,925
PrEP drugs $19,116 $3267 $2786 $22,496 $24,881 $16,655 $1053 $90,252
HIV tests (weeks 4, 12, 28, 36, 48, 60, 72, 84) $11,606 $2274 $1755 $13,287 $12,762 $9109 $309 $51,102
Phone charges $5,328 $1,066 $888 $1,066 $1,066 $1,066 $10,478
Total Incremental continuation visit costs $64,041 $14,175 $11,460 $65,437 $75,364 $48,093 $2110 $280,679
Full cost  initiationa $228,590 $102,230 $71,946 $111,744 $168,617 $146,586 $3036 $832,751
# of initiation visits 1599 500 351 644 807 716 60 4677
Full cost per initiation visit $143 $204 $205 $174 $209 $205 $51 $178
# of continuation visits 2645 504 388 3081 3405 2468 151 12,642
Incremental cost per continuation visit $24 $28 $30 $21 $22 $19 $14 $22
Average # continuation visits per client 1.7 1.0 1.1 4.8 4.2 3.4 2.5 2.7
Average duration per client in months 1.8 0.9 0.7 4.6 5.6 3.7 n/a 3.0
Average cost per person year $1208 $3037 $4025 $710 $642 $876 n/a $943
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13.1 weeks overall, generating an average $pPY cost of $943 
($642–$4025 across PSI clinics) (Table 3).
By population, the average duration of continuation was 
15.0 weeks for AGYW, 15.4 weeks for adult women and 
9.3 weeks for all men. Figure 2 models out costs and num-
bers of clients needed to initiate across different average 
durations of continuation. For shorter continuation, more 
people need to be initiated to achieve a person-year receiv-
ing oral PrEP. For longer continuation, the fixed costs of 
initiation are spread over a longer time, reducing average 
$pPY of receiving oral PrEP. However, given differences in 
how long people continue on PrEP, $pPY shows more vari-
ability. While women of all age groups continued on PrEP 
for similar durations, resulting in very similar $pPY ($839 
and $857, respectively among AGYW and adult women), 
men tended to discontinue PrEP sooner, with a consequent 
$pPY of $1,219.
Sensitivity and Scenario Analysis
Supplemental Figure A3 depicts univariate and multivariate 
sensitivity and scenario analyses results for average costs per 
person initiated. Average costs remain largely robust under 
varying parameter specifications. Varying salary levels of 
PrEP providers 10% upwards and downwards resulted in 
respective average costs per client initiated of $229 and $246 
(base case $238). When the price of PrEP drug was varied 
by 20% to assess the impact of price changes, average cost 
per client initiated was $236 and $240. Best- and worst-
case scenarios, with all parameters yielding lowest/highest 
average cost per person initiated, resulted in average cost per 
client initiated of $222 and $249, respectively. Assessing 
costs without the EPM incentives resulted in average cost 
per client initiated of $225; however, this estimate assumes 
that uptake would not be affected. A full description of sen-
sitivity analysis on the average cost per client continued at 
months three and six can be found in Supplement A1.
Discussion
We estimated the annual total and unit economic costs of 
delivering oral PrEP to clients as part of integrated HIV and 
SRH services at seven Zimbabwe clinic sites. Total annual 
program costs were $1,113,430 and average costs for PSI 
$238, ranging from $183 at the largest facility in Harare 
(Site 1) to $302 at the smallest clinic (Site 5). Average costs 
appear lower at sites initiating larger numbers of PrEP cli-
ents, although an exception is the far lower initiation cost 
($86) at the government SGBV site. Similar to other PrEP 
programs in sub-Saharan Africa costs in this study increase 
as clients discontinue PrEP [17–19].
Recent data from the POWER study [31] in Kenya 
and South Africa revealed that 25% (160/644) of AGYW 
restarted PrEP after a brief discontinuation [32]. This 
finding is consistent with findings of PrEP cycling in 
other regional programs, although few currently track 
PrEP restarts. Any restart at the sites in our study would 
have been captured as a costlier new PrEP initiation, mak-
ing it difficult to estimate the true average cost per client 
26.0 
8.7 




$942 $839 $857 







































Average weeks of connuaon per person
Line: Cost per PY of receiving oral PrEP = $iniaons * QiniaonsNeeded + $follow up visits 
* QaveFUs pp * Qiniaons Needed
Bar height: numbers needed to iniate to achieve a year of PrEP exposure, at 
different duraons of connuaon
Fig. 2  Cost per person-year and numbers needed to initiate by average continuation duration for Zimbabwe sites offering PrEP (2018)
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if that client cycled on and off PrEP. Nevertheless, the 
finding of increased costs for sites with higher discon-
tinuation rates, as seen in the PSI sites, merits further 
examination. One contributory factor could be the use of 
incentivized demand creation (via EPMs) for PrEP initia-
tions, but not for follow-up and ongoing support of PrEP 
users.
Results show large variation across the sites, which 
influenced average costs. Varying lengths of PrEP pro-
gram maturity help explain differences in average costs, 
because sites that began providing PrEP relatively earlier 
benefited from a longer period of program learning. Sites 
seeing more clients had lower average costs, highlight-
ing potential economies of scale. Average costs were also 
influenced by type of staff employed, as sites employed 
staff with differing levels of specialization, and by how 
much staff were paid. Only three sites, for example, 
employed full-time doctors; the rest employed doctors 
for one day a week and for two to three hours on those 
days, depending on the volume of clients. It is therefore 
not surprising that the sites employing higher specializa-
tion cadres and with staff who were paid more tended to 
have higher costs highlighting potential cost savings if 
task shifting to lower, less paid cadres is implemented as 
shown by the government SGBV clinic.
Approaches to demand creation also influenced vari-
ation in average costs across sites; sites such as the gov-
ernment SGBV clinic and a smaller NGO clinic lacked 
funding for and therefore implemented few demand crea-
tion activities. The managers of those sites also expressed 
a fear of potentially creating unsustainable demand for 
PrEP in an environment of observed or anticipated drug 
stockouts.
Costs compare well with estimates elsewhere. A study 
in Kenya estimated the total and incremental cost of deliv-
ering PrEP integrated into a government health facility 
ART program, respectively, at $250 and $87 per couple 
per year [18]. Another study in Kenya found an average 
annual total cost of $602 for providing oral PrEP to one 
sex worker through the clinics of a sex worker outreach 
program (SWOP), including both direct and indirect costs 
[19], with personnel, PrEP drug and laboratory testing 
accounting for most of the cost differences compared to 
our findings. In our study laboratory testing costs consti-
tute only 2% of costs because the programme funded labo-
ratories in the PrEP sites perform this service at cost than 
would be the case if clients had to seek these services at 
private laboratories. Our initiation numbers suggest labo-
ratory testing can restrict distribution mainly to sites that 
are large enough to have laboratories. Experience from 
elsewhere however has also shown higher costs of labora-
tory testing for creatinine and other tests to be a barrier 
to PrEP service delivery [10, 13, 33]. In Uganda, a study 
found that the annual cost of PrEP delivery for serodis-
cordant couples was $408 per couple in the study setting 
and $92 per couple in the government setting [17].
Limitations
This study has several limitations. As noted, the sites 
included in the study did not track PrEP cycling, so any 
restarts would have been categorized as PrEP initiations, 
which have higher associated costs than restart or con-
tinuation visits. For this analysis, we deliberately selected 
seven sites that had already been providing PrEP for long 
enough to provide a year’s worth of cost data. A larger 
number of sites would provide more variability of average 
costs and greater insight into the cost drivers.
This average cost study is also limited to a provider per-
spective, excluding user costs incurred by clients seeking 
PrEP services. A costing study of the Jhpiego-led Jilinde 
project in Kenya includes the client as well as the provider 
costs of PrEP scale-up throughout Kenya, in preparation 
for national budgeting of future scale-up and to inform 
recommendations about which service delivery models are 
most effective at reaching specific populations [17, 18]. 
With more time and funding, this Zimbabwe PrEP study 
would have benefited from an exploration of the client 
costs of PrEP use and their potential as a contributor to not 
only uptake but also low continuation rates.
Conclusions
Despite the above limitations, this costing study provides 
valuable information on the initiation and continuation 
costs of PrEP delivery services in Zimbabwe. A strength 
of this study is its ability to generate estimates of initiation 
and continuation costs based on actual program delivery 
experience. The analysis reveals ways by which costs can 
be reduced, most significantly through increased PrEP 
continuation. The findings of this costing study are both 
relevant and timely, as they come just as Zimbabwe begins 
to scale up PrEP delivery.
PrEP program outputs show high demand for PrEP 
across sites. However, challenges with continuation are 
evident and affect average costs, which increase rapidly 
as client continuation numbers drop off. As shown in this 
analysis a substantial proportion of PrEP clients drop off 
before the first month, some failing to return even for fol-
low-up visit 1. This suggests that some people initiate and 
incur costs, though they either do not perceive themselves 
at risk or cannot overcome barriers to sustain PrEP use. 
Programs would benefit from economies of scale achieved 
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through higher continuation rates albeit for those clients 
who continue to be at risk. Further research will help high-
light what proportion of discontinuation is based on cli-
ents being no longer at risk, and what proportion is due to 
other reasons that could be managed, such as stigma, side 
effects, or the burden of regular pill-taking, including stor-
age, consumption and knowledge of regimen [34]. It may 
also be important to assess the affordability and impact of 
extending the incentive for initiations to follow-up visits, 
in order to promote continued engagement where clients 
continue to be at risk. Such research will help frame strate-
gies to improve continuation for those who still consider 
themselves at risk, to allow for natural cycling on and off 
PrEP when indicated together with better identification 
of clients more likely to continue use and those needing 
additional support. Tracking longitudinal client data to 
account for PrEP restarts will improve the accuracy of 
cost estimates and supporting clients at risk to continue 
on PrEP will improve program efficiency by spreading the 
fixed costs of initiation over more months of receiving 
oral PrEP.
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